| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Coronary Disease | 20 | 2017 | 181 | 3.620 |
Why?
|
| Coronary Artery Disease | 31 | 2017 | 134 | 3.450 |
Why?
|
| Cardiovascular Diseases | 23 | 2024 | 598 | 3.080 |
Why?
|
| Calcinosis | 17 | 2017 | 40 | 2.880 |
Why?
|
| European Continental Ancestry Group | 29 | 2017 | 529 | 2.590 |
Why?
|
| Asthma | 18 | 2016 | 385 | 2.450 |
Why?
|
| Humans | 173 | 2024 | 17611 | 2.300 |
Why?
|
| Female | 149 | 2024 | 12608 | 2.300 |
Why?
|
| Genome-Wide Association Study | 22 | 2022 | 243 | 2.250 |
Why?
|
| Male | 136 | 2021 | 10008 | 2.190 |
Why?
|
| Polymorphism, Single Nucleotide | 33 | 2022 | 373 | 2.170 |
Why?
|
| Middle Aged | 113 | 2024 | 7911 | 2.150 |
Why?
|
| Risk Factors | 79 | 2024 | 3325 | 2.150 |
Why?
|
| Long QT Syndrome | 4 | 2021 | 6 | 2.110 |
Why?
|
| Breast Diseases | 5 | 2020 | 17 | 1.950 |
Why?
|
| Adult | 91 | 2022 | 7598 | 1.820 |
Why?
|
| Aged | 82 | 2024 | 6095 | 1.760 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 16 | 2015 | 197 | 1.610 |
Why?
|
| Electrocardiography | 7 | 2021 | 42 | 1.580 |
Why?
|
| Heart Failure | 8 | 2024 | 396 | 1.540 |
Why?
|
| Cohort Studies | 50 | 2021 | 2570 | 1.530 |
Why?
|
| Cerebrovascular Disorders | 3 | 2017 | 34 | 1.520 |
Why?
|
| Tobacco Smoke Pollution | 9 | 2010 | 34 | 1.520 |
Why?
|
| California | 39 | 2020 | 2284 | 1.430 |
Why?
|
| African Americans | 16 | 2017 | 472 | 1.430 |
Why?
|
| Smoking | 15 | 2012 | 483 | 1.340 |
Why?
|
| Electronic Health Records | 4 | 2023 | 681 | 1.300 |
Why?
|
| Omalizumab | 3 | 2017 | 4 | 1.150 |
Why?
|
| Hispanic Americans | 8 | 2017 | 404 | 1.120 |
Why?
|
| Myocardial Infarction | 9 | 2011 | 238 | 1.120 |
Why?
|
| Prospective Studies | 35 | 2024 | 1267 | 1.080 |
Why?
|
| Anti-Asthmatic Agents | 2 | 2017 | 85 | 1.070 |
Why?
|
| Asian Americans | 5 | 2017 | 176 | 1.010 |
Why?
|
| Predictive Value of Tests | 15 | 2017 | 351 | 0.940 |
Why?
|
| Case-Control Studies | 28 | 2021 | 1115 | 0.930 |
Why?
|
| Mammography | 4 | 2017 | 169 | 0.920 |
Why?
|
| Hypersensitivity | 2 | 2017 | 18 | 0.910 |
Why?
|
| Incidence | 24 | 2017 | 1255 | 0.890 |
Why?
|
| Delivery of Health Care, Integrated | 5 | 2021 | 531 | 0.880 |
Why?
|
| Continental Population Groups | 5 | 2017 | 302 | 0.880 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2023 | 5 | 0.870 |
Why?
|
| Kidney Failure, Chronic | 7 | 2011 | 147 | 0.850 |
Why?
|
| Prognosis | 14 | 2022 | 606 | 0.840 |
Why?
|
| Aged, 80 and over | 24 | 2020 | 1900 | 0.830 |
Why?
|
| Arrhythmias, Cardiac | 4 | 2024 | 32 | 0.820 |
Why?
|
| Algorithms | 8 | 2023 | 233 | 0.820 |
Why?
|
| Postmenopause | 3 | 2020 | 241 | 0.820 |
Why?
|
| Breast | 3 | 2017 | 84 | 0.810 |
Why?
|
| Health Status Disparities | 2 | 2017 | 146 | 0.810 |
Why?
|
| Blood Pressure | 9 | 2020 | 298 | 0.810 |
Why?
|
| African Continental Ancestry Group | 14 | 2016 | 162 | 0.800 |
Why?
|
| Hostility | 6 | 2015 | 7 | 0.790 |
Why?
|
| Torsades de Pointes | 1 | 2021 | 1 | 0.790 |
Why?
|
| Myocardial Ischemia | 1 | 2021 | 24 | 0.780 |
Why?
|
| Metabolic Syndrome | 5 | 2016 | 80 | 0.780 |
Why?
|
| Genetic Predisposition to Disease | 17 | 2016 | 368 | 0.760 |
Why?
|
| Phenotype | 11 | 2022 | 149 | 0.690 |
Why?
|
| Cognitive Dysfunction | 1 | 2020 | 47 | 0.690 |
Why?
|
| Tomography, X-Ray Computed | 10 | 2009 | 205 | 0.690 |
Why?
|
| Incidental Findings | 3 | 2009 | 26 | 0.680 |
Why?
|
| Age Factors | 17 | 2016 | 917 | 0.660 |
Why?
|
| Stroke | 5 | 2017 | 311 | 0.660 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2017 | 13 | 0.660 |
Why?
|
| Dementia | 1 | 2020 | 106 | 0.640 |
Why?
|
| Quantitative Trait Loci | 5 | 2022 | 36 | 0.630 |
Why?
|
| Lung | 3 | 2023 | 62 | 0.620 |
Why?
|
| Severity of Illness Index | 15 | 2015 | 454 | 0.620 |
Why?
|
| Biomarkers | 12 | 2016 | 301 | 0.610 |
Why?
|
| Proportional Hazards Models | 14 | 2022 | 709 | 0.600 |
Why?
|
| Disability Evaluation | 5 | 2012 | 46 | 0.600 |
Why?
|
| Reproductive History | 1 | 2017 | 17 | 0.600 |
Why?
|
| Risk Assessment | 14 | 2016 | 1097 | 0.590 |
Why?
|
| Databases, Factual | 3 | 2017 | 309 | 0.560 |
Why?
|
| Adolescent | 23 | 2015 | 3651 | 0.550 |
Why?
|
| Health Status | 11 | 2010 | 298 | 0.550 |
Why?
|
| Prevalence | 13 | 2017 | 884 | 0.550 |
Why?
|
| Aging | 5 | 2015 | 161 | 0.550 |
Why?
|
| Environmental Exposure | 2 | 2010 | 116 | 0.540 |
Why?
|
| Health Maintenance Organizations | 7 | 2017 | 417 | 0.530 |
Why?
|
| Troponin I | 1 | 2016 | 8 | 0.530 |
Why?
|
| Genetic Testing | 1 | 2016 | 70 | 0.530 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 3 | 2011 | 5 | 0.510 |
Why?
|
| Phospholipases A | 2 | 2006 | 2 | 0.510 |
Why?
|
| Breast Neoplasms | 4 | 2024 | 949 | 0.500 |
Why?
|
| Cholesterol | 4 | 2007 | 106 | 0.490 |
Why?
|
| Linear Models | 10 | 2016 | 231 | 0.490 |
Why?
|
| Cross-Sectional Studies | 12 | 2020 | 1322 | 0.490 |
Why?
|
| Hospitalization | 12 | 2020 | 797 | 0.480 |
Why?
|
| Sex Factors | 11 | 2013 | 643 | 0.480 |
Why?
|
| Time Factors | 9 | 2017 | 1086 | 0.480 |
Why?
|
| Follow-Up Studies | 19 | 2016 | 1210 | 0.470 |
Why?
|
| Aortic Diseases | 2 | 2007 | 2 | 0.470 |
Why?
|
| Arginine | 3 | 2010 | 12 | 0.470 |
Why?
|
| Fatty Acids, Omega-3 | 3 | 2016 | 22 | 0.460 |
Why?
|
| Occupational Exposure | 4 | 2008 | 67 | 0.460 |
Why?
|
| Surveys and Questionnaires | 13 | 2015 | 1309 | 0.450 |
Why?
|
| Heart | 3 | 2020 | 13 | 0.440 |
Why?
|
| Longitudinal Studies | 10 | 2019 | 710 | 0.430 |
Why?
|
| Carotenoids | 3 | 2010 | 29 | 0.430 |
Why?
|
| Odds Ratio | 10 | 2019 | 671 | 0.420 |
Why?
|
| Heart Diseases | 2 | 2005 | 77 | 0.420 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 107 | 0.410 |
Why?
|
| Life Style | 4 | 2017 | 332 | 0.400 |
Why?
|
| Body Mass Index | 14 | 2015 | 958 | 0.400 |
Why?
|
| Genetic Loci | 5 | 2016 | 55 | 0.400 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2024 | 171 | 0.400 |
Why?
|
| Comorbidity | 5 | 2017 | 594 | 0.400 |
Why?
|
| Logistic Models | 12 | 2013 | 926 | 0.400 |
Why?
|
| Respiratory Function Tests | 5 | 2019 | 32 | 0.400 |
Why?
|
| Genome, Human | 6 | 2015 | 32 | 0.390 |
Why?
|
| Radiographic Image Enhancement | 2 | 2009 | 3 | 0.390 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 2 | 2009 | 7 | 0.390 |
Why?
|
| Angiopoietin-1 | 1 | 2011 | 2 | 0.390 |
Why?
|
| Angiopoietin-2 | 1 | 2011 | 2 | 0.390 |
Why?
|
| Receptor, TIE-2 | 1 | 2011 | 2 | 0.390 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 3 | 0.390 |
Why?
|
| Neovascularization, Physiologic | 1 | 2011 | 3 | 0.390 |
Why?
|
| Health | 3 | 2015 | 33 | 0.370 |
Why?
|
| Genotype | 14 | 2015 | 227 | 0.370 |
Why?
|
| Ischemic Attack, Transient | 2 | 2017 | 27 | 0.370 |
Why?
|
| Seafood | 2 | 2016 | 8 | 0.360 |
Why?
|
| Hypertension | 5 | 2016 | 500 | 0.360 |
Why?
|
| Postural Balance | 2 | 2008 | 10 | 0.360 |
Why?
|
| Multivariate Analysis | 11 | 2013 | 568 | 0.360 |
Why?
|
| Anaphylaxis | 1 | 2010 | 15 | 0.360 |
Why?
|
| Environmental Monitoring | 1 | 2010 | 26 | 0.350 |
Why?
|
| United States | 20 | 2017 | 3956 | 0.350 |
Why?
|
| Body Height | 5 | 2013 | 62 | 0.340 |
Why?
|
| Health Policy | 2 | 2007 | 122 | 0.330 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 2 | 2020 | 5 | 0.330 |
Why?
|
| Social Support | 2 | 2008 | 203 | 0.320 |
Why?
|
| Muscle Strength | 5 | 2012 | 12 | 0.320 |
Why?
|
| Atherosclerosis | 3 | 2020 | 51 | 0.320 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2021 | 35 | 0.320 |
Why?
|
| Heart Rate | 3 | 2013 | 40 | 0.320 |
Why?
|
| Quality of Life | 8 | 2009 | 507 | 0.310 |
Why?
|
| Consumer Behavior | 1 | 2008 | 29 | 0.310 |
Why?
|
| Language | 1 | 2008 | 51 | 0.310 |
Why?
|
| Socioeconomic Factors | 8 | 2012 | 630 | 0.310 |
Why?
|
| Confidence Intervals | 5 | 2012 | 237 | 0.310 |
Why?
|
| Walking | 3 | 2009 | 85 | 0.300 |
Why?
|
| Social Class | 2 | 2008 | 120 | 0.300 |
Why?
|
| Obesity | 6 | 2015 | 837 | 0.300 |
Why?
|
| Acute Coronary Syndrome | 1 | 2008 | 18 | 0.300 |
Why?
|
| Health Education | 1 | 2008 | 111 | 0.300 |
Why?
|
| Workplace | 2 | 2007 | 30 | 0.300 |
Why?
|
| Body Composition | 2 | 2010 | 82 | 0.300 |
Why?
|
| Asymptomatic Diseases | 3 | 2016 | 29 | 0.290 |
Why?
|
| Analysis of Variance | 6 | 2013 | 159 | 0.290 |
Why?
|
| Multiphasic Screening | 1 | 2007 | 8 | 0.290 |
Why?
|
| Angina Pectoris | 4 | 2007 | 16 | 0.290 |
Why?
|
| Fishes | 3 | 2016 | 10 | 0.290 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2007 | 6 | 0.290 |
Why?
|
| Asian Continental Ancestry Group | 7 | 2016 | 90 | 0.290 |
Why?
|
| Neoplasms | 3 | 2006 | 438 | 0.290 |
Why?
|
| Respiration | 1 | 2007 | 8 | 0.280 |
Why?
|
| Motor Activity | 4 | 2011 | 212 | 0.280 |
Why?
|
| Health Behavior | 2 | 2010 | 359 | 0.280 |
Why?
|
| Abdomen | 1 | 2006 | 20 | 0.280 |
Why?
|
| Leptin | 1 | 2006 | 29 | 0.280 |
Why?
|
| Lung Neoplasms | 2 | 2009 | 255 | 0.280 |
Why?
|
| Diabetic Nephropathies | 1 | 2006 | 26 | 0.280 |
Why?
|
| Health Services Accessibility | 2 | 2007 | 289 | 0.270 |
Why?
|
| Lung Diseases, Obstructive | 2 | 2012 | 11 | 0.270 |
Why?
|
| Child | 6 | 2017 | 2474 | 0.270 |
Why?
|
| Endostatins | 1 | 2006 | 1 | 0.270 |
Why?
|
| Depression | 4 | 2009 | 502 | 0.270 |
Why?
|
| Adiposity | 1 | 2006 | 66 | 0.260 |
Why?
|
| Sex Distribution | 7 | 2017 | 190 | 0.260 |
Why?
|
| Computational Biology | 2 | 2015 | 27 | 0.250 |
Why?
|
| Sensitivity and Specificity | 4 | 2017 | 304 | 0.250 |
Why?
|
| Personality | 2 | 2015 | 9 | 0.250 |
Why?
|
| Television | 2 | 2015 | 22 | 0.250 |
Why?
|
| Critical Care | 1 | 2005 | 71 | 0.240 |
Why?
|
| Coronary Vessels | 3 | 2011 | 15 | 0.230 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2004 | 3 | 0.230 |
Why?
|
| Air Pollution, Indoor | 1 | 2004 | 7 | 0.230 |
Why?
|
| Age of Onset | 4 | 2008 | 79 | 0.230 |
Why?
|
| Retrospective Studies | 10 | 2013 | 2447 | 0.230 |
Why?
|
| Molecular Epidemiology | 6 | 2015 | 44 | 0.220 |
Why?
|
| Alcohol Drinking | 4 | 2011 | 368 | 0.220 |
Why?
|
| Anthropometry | 2 | 2013 | 66 | 0.220 |
Why?
|
| Respiratory Tract Diseases | 2 | 2006 | 25 | 0.210 |
Why?
|
| Mental Disorders | 2 | 2010 | 280 | 0.210 |
Why?
|
| Cancer Survivors | 1 | 2024 | 83 | 0.210 |
Why?
|
| Lipids | 3 | 2013 | 77 | 0.210 |
Why?
|
| Survival Analysis | 2 | 2017 | 215 | 0.210 |
Why?
|
| Chromosome Mapping | 3 | 2010 | 17 | 0.200 |
Why?
|
| Genetic Variation | 3 | 2012 | 77 | 0.200 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2022 | 20 | 0.200 |
Why?
|
| Spirometry | 6 | 2019 | 65 | 0.200 |
Why?
|
| Ethnic Groups | 4 | 2016 | 485 | 0.200 |
Why?
|
| Thyroid Neoplasms | 1 | 2001 | 11 | 0.190 |
Why?
|
| Medication Adherence | 1 | 2024 | 244 | 0.190 |
Why?
|
| Educational Status | 4 | 2011 | 200 | 0.190 |
Why?
|
| Blood Glucose | 2 | 2016 | 341 | 0.190 |
Why?
|
| Alanine Transaminase | 1 | 2001 | 21 | 0.190 |
Why?
|
| Cholesterol, HDL | 4 | 2016 | 79 | 0.180 |
Why?
|
| Waist-Hip Ratio | 5 | 2013 | 23 | 0.180 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2020 | 2 | 0.180 |
Why?
|
| Diabetes Complications | 1 | 2001 | 114 | 0.180 |
Why?
|
| Diet | 3 | 2024 | 365 | 0.180 |
Why?
|
| Cholesterol, LDL | 4 | 2016 | 119 | 0.180 |
Why?
|
| Kidney Diseases | 3 | 2011 | 53 | 0.180 |
Why?
|
| Aorta, Thoracic | 1 | 2000 | 2 | 0.180 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2000 | 4 | 0.180 |
Why?
|
| Reproducibility of Results | 7 | 2010 | 381 | 0.180 |
Why?
|
| Risk | 5 | 2014 | 516 | 0.170 |
Why?
|
| Respiratory Distress Syndrome, Adult | 1 | 2000 | 9 | 0.170 |
Why?
|
| Vasodilation | 2 | 2011 | 8 | 0.170 |
Why?
|
| Sex Characteristics | 4 | 2015 | 69 | 0.170 |
Why?
|
| Uric Acid | 3 | 2009 | 9 | 0.170 |
Why?
|
| Pulmonary Emphysema | 1 | 2019 | 11 | 0.170 |
Why?
|
| Forced Expiratory Volume | 6 | 2019 | 69 | 0.170 |
Why?
|
| Health Surveys | 3 | 2010 | 260 | 0.170 |
Why?
|
| Suicide, Attempted | 1 | 2000 | 96 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 129 | 0.160 |
Why?
|
| Genetic Markers | 2 | 2016 | 25 | 0.160 |
Why?
|
| Central America | 2 | 2009 | 4 | 0.160 |
Why?
|
| Chi-Square Distribution | 4 | 2011 | 154 | 0.160 |
Why?
|
| Mexico | 2 | 2009 | 19 | 0.160 |
Why?
|
| Cross Infection | 1 | 1998 | 27 | 0.160 |
Why?
|
| Cardiovascular Agents | 2 | 2024 | 24 | 0.160 |
Why?
|
| Animals | 5 | 2016 | 259 | 0.150 |
Why?
|
| Triglycerides | 3 | 2013 | 86 | 0.150 |
Why?
|
| Alleles | 4 | 2011 | 84 | 0.150 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2015 | 23 | 0.150 |
Why?
|
| Arteries | 1 | 2017 | 8 | 0.150 |
Why?
|
| Blood Coagulation Factors | 2 | 2007 | 10 | 0.150 |
Why?
|
| Intracranial Hemorrhages | 1 | 2017 | 16 | 0.150 |
Why?
|
| Calcium | 3 | 2007 | 34 | 0.150 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 415 | 0.150 |
Why?
|
| Oceanic Ancestry Group | 1 | 2017 | 33 | 0.150 |
Why?
|
| Brain Ischemia | 1 | 2017 | 37 | 0.150 |
Why?
|
| Indians, North American | 1 | 2017 | 49 | 0.150 |
Why?
|
| Treatment Outcome | 4 | 2014 | 1259 | 0.140 |
Why?
|
| Abdominal Fat | 2 | 2007 | 14 | 0.140 |
Why?
|
| Gene Frequency | 7 | 2013 | 43 | 0.140 |
Why?
|
| Placebo Effect | 1 | 2017 | 7 | 0.140 |
Why?
|
| Young Adult | 6 | 2016 | 2427 | 0.140 |
Why?
|
| Tibial Arteries | 2 | 2020 | 5 | 0.140 |
Why?
|
| Population Surveillance | 3 | 2007 | 263 | 0.140 |
Why?
|
| Chromosomes, Human, X | 1 | 2016 | 2 | 0.140 |
Why?
|
| International Classification of Diseases | 1 | 2017 | 85 | 0.140 |
Why?
|
| Protective Factors | 1 | 2016 | 32 | 0.140 |
Why?
|
| Double-Blind Method | 1 | 2017 | 155 | 0.140 |
Why?
|
| Activities of Daily Living | 4 | 2012 | 85 | 0.140 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 382 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2010 | 375 | 0.130 |
Why?
|
| Up-Regulation | 1 | 2016 | 7 | 0.130 |
Why?
|
| Contraceptives, Oral | 2 | 2013 | 26 | 0.130 |
Why?
|
| Managed Care Programs | 3 | 2008 | 325 | 0.130 |
Why?
|
| Interviews as Topic | 4 | 2012 | 305 | 0.130 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2016 | 95 | 0.130 |
Why?
|
| Phospholipases A2 | 2 | 2006 | 2 | 0.130 |
Why?
|
| Carotid Artery Diseases | 2 | 2009 | 12 | 0.130 |
Why?
|
| Genotyping Techniques | 1 | 2015 | 26 | 0.130 |
Why?
|
| Urban Population | 2 | 2007 | 116 | 0.130 |
Why?
|
| Telomere | 1 | 2015 | 19 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 322 | 0.130 |
Why?
|
| Wounds and Injuries | 1 | 2015 | 47 | 0.120 |
Why?
|
| Overweight | 2 | 2009 | 269 | 0.120 |
Why?
|
| Genomics | 1 | 2015 | 55 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 4 | 2011 | 153 | 0.120 |
Why?
|
| Membrane Proteins | 2 | 2020 | 38 | 0.120 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2013 | 6 | 0.120 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2014 | 2 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 24 | 0.120 |
Why?
|
| Exercise Tolerance | 2 | 2011 | 13 | 0.110 |
Why?
|
| Survival Rate | 3 | 2003 | 260 | 0.110 |
Why?
|
| Risk Adjustment | 1 | 2013 | 24 | 0.110 |
Why?
|
| Cross-Over Studies | 1 | 2013 | 45 | 0.110 |
Why?
|
| Body Weights and Measures | 1 | 2013 | 12 | 0.110 |
Why?
|
| Exercise Test | 5 | 2013 | 44 | 0.110 |
Why?
|
| Body Weight | 2 | 2013 | 219 | 0.110 |
Why?
|
| Insulin | 3 | 2009 | 205 | 0.110 |
Why?
|
| Skin Neoplasms | 1 | 2014 | 57 | 0.110 |
Why?
|
| Meta-Analysis as Topic | 4 | 2016 | 32 | 0.110 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2010 | 10 | 0.110 |
Why?
|
| Physical Fitness | 2 | 2012 | 73 | 0.110 |
Why?
|
| Proteins | 1 | 2012 | 16 | 0.110 |
Why?
|
| Health Expenditures | 1 | 2013 | 75 | 0.100 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2012 | 26 | 0.100 |
Why?
|
| Nitroglycerin | 2 | 2011 | 6 | 0.100 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 2 | 0.100 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2011 | 8 | 0.100 |
Why?
|
| Vasodilator Agents | 2 | 2011 | 9 | 0.100 |
Why?
|
| Blood Cells | 1 | 2012 | 4 | 0.100 |
Why?
|
| Research Design | 3 | 2009 | 374 | 0.100 |
Why?
|
| Income | 2 | 2013 | 90 | 0.100 |
Why?
|
| Health Services | 2 | 2020 | 112 | 0.100 |
Why?
|
| Angina, Stable | 1 | 2011 | 4 | 0.100 |
Why?
|
| Coronary Circulation | 1 | 2011 | 4 | 0.100 |
Why?
|
| Atrial Fibrillation | 1 | 2013 | 170 | 0.100 |
Why?
|
| High-Throughput Screening Assays | 1 | 2011 | 4 | 0.100 |
Why?
|
| Brachial Artery | 1 | 2011 | 6 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2010 | 748 | 0.100 |
Why?
|
| Respiratory Muscles | 1 | 2011 | 1 | 0.090 |
Why?
|
| Ankle Brachial Index | 1 | 2011 | 8 | 0.090 |
Why?
|
| Peripheral Arterial Disease | 1 | 2011 | 13 | 0.090 |
Why?
|
| Lower Extremity | 1 | 2011 | 12 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 17 | 0.090 |
Why?
|
| Self Care | 2 | 2009 | 163 | 0.090 |
Why?
|
| Tryptophan | 1 | 2010 | 3 | 0.090 |
Why?
|
| Kinesin | 1 | 2010 | 3 | 0.090 |
Why?
|
| Muscle, Skeletal | 1 | 2011 | 33 | 0.090 |
Why?
|
| Disabled Persons | 2 | 2012 | 35 | 0.090 |
Why?
|
| Hypoxia | 1 | 2010 | 8 | 0.090 |
Why?
|
| Tunica Media | 2 | 2009 | 5 | 0.090 |
Why?
|
| Tunica Intima | 2 | 2009 | 9 | 0.090 |
Why?
|
| Oxygen | 1 | 2010 | 16 | 0.090 |
Why?
|
| Chronic Disease | 4 | 2013 | 428 | 0.090 |
Why?
|
| Epistasis, Genetic | 1 | 2010 | 3 | 0.090 |
Why?
|
| Genome | 1 | 2010 | 3 | 0.090 |
Why?
|
| Cognition Disorders | 1 | 2010 | 31 | 0.090 |
Why?
|
| Angioedema | 1 | 2010 | 6 | 0.090 |
Why?
|
| Receptors, Nicotinic | 1 | 2010 | 9 | 0.090 |
Why?
|
| Health Care Surveys | 2 | 2008 | 230 | 0.090 |
Why?
|
| Statistics, Nonparametric | 3 | 2010 | 50 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 103 | 0.090 |
Why?
|
| Epidemiological Monitoring | 1 | 2010 | 25 | 0.090 |
Why?
|
| Coronary Angiography | 1 | 2009 | 21 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 60 | 0.090 |
Why?
|
| Anxiety Disorders | 1 | 2010 | 91 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 2 | 2008 | 15 | 0.080 |
Why?
|
| Angiography | 1 | 2009 | 12 | 0.080 |
Why?
|
| Nocturia | 1 | 2009 | 4 | 0.080 |
Why?
|
| West Indies | 1 | 2009 | 1 | 0.080 |
Why?
|
| South America | 1 | 2009 | 4 | 0.080 |
Why?
|
| Emergency Service, Hospital | 3 | 2009 | 358 | 0.080 |
Why?
|
| Proteinuria | 1 | 2009 | 26 | 0.080 |
Why?
|
| C-Reactive Protein | 2 | 2008 | 58 | 0.080 |
Why?
|
| Hemoglobins | 1 | 2009 | 39 | 0.080 |
Why?
|
| Multilingualism | 1 | 2008 | 7 | 0.080 |
Why?
|
| Regression Analysis | 4 | 2012 | 297 | 0.080 |
Why?
|
| Reference Values | 4 | 2013 | 91 | 0.080 |
Why?
|
| Epidemiologic Methods | 2 | 2010 | 81 | 0.080 |
Why?
|
| Women's Health | 2 | 2013 | 200 | 0.080 |
Why?
|
| Dust | 1 | 2008 | 22 | 0.080 |
Why?
|
| Inflammation Mediators | 1 | 2008 | 7 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2008 | 7 | 0.080 |
Why?
|
| Occupational Diseases | 1 | 2008 | 41 | 0.080 |
Why?
|
| Scavenger Receptors, Class E | 1 | 2008 | 3 | 0.080 |
Why?
|
| Phantoms, Imaging | 1 | 2008 | 4 | 0.080 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2008 | 4 | 0.080 |
Why?
|
| Insulin Resistance | 1 | 2009 | 133 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2008 | 13 | 0.080 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2008 | 12 | 0.080 |
Why?
|
| Mental Health | 1 | 2010 | 165 | 0.080 |
Why?
|
| Age Distribution | 3 | 2017 | 246 | 0.080 |
Why?
|
| Smoking Cessation | 2 | 2007 | 193 | 0.080 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 2007 | 3 | 0.080 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2007 | 3 | 0.080 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2007 | 4 | 0.080 |
Why?
|
| Matrix Metalloproteinases | 1 | 2007 | 4 | 0.080 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2007 | 7 | 0.080 |
Why?
|
| Arachidonate 12-Lipoxygenase | 1 | 2007 | 4 | 0.080 |
Why?
|
| Arachidonate 15-Lipoxygenase | 1 | 2007 | 4 | 0.080 |
Why?
|
| Tocopherols | 1 | 2007 | 5 | 0.070 |
Why?
|
| Community Networks | 1 | 2008 | 24 | 0.070 |
Why?
|
| Inflammation | 1 | 2008 | 62 | 0.070 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 4 | 0.070 |
Why?
|
| Chemokines | 1 | 2007 | 8 | 0.070 |
Why?
|
| Sweden | 1 | 2007 | 19 | 0.070 |
Why?
|
| Calcification, Physiologic | 1 | 2007 | 1 | 0.070 |
Why?
|
| Recurrence | 1 | 2008 | 186 | 0.070 |
Why?
|
| Endothelium, Vascular | 1 | 2007 | 5 | 0.070 |
Why?
|
| Infant, Newborn | 1 | 2010 | 844 | 0.070 |
Why?
|
| Aorta, Abdominal | 1 | 2007 | 1 | 0.070 |
Why?
|
| Risk Management | 1 | 2007 | 3 | 0.070 |
Why?
|
| Electric Impedance | 1 | 2007 | 7 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2007 | 38 | 0.070 |
Why?
|
| Occupational Health | 1 | 2007 | 17 | 0.070 |
Why?
|
| Carotid Artery, Common | 1 | 2006 | 2 | 0.070 |
Why?
|
| Internal-External Control | 1 | 2006 | 12 | 0.070 |
Why?
|
| Disease Progression | 3 | 2014 | 264 | 0.070 |
Why?
|
| Respiration, Artificial | 1 | 2007 | 37 | 0.070 |
Why?
|
| Smoking Prevention | 1 | 2007 | 54 | 0.070 |
Why?
|
| Internet | 1 | 2008 | 231 | 0.070 |
Why?
|
| Self Concept | 1 | 2006 | 39 | 0.070 |
Why?
|
| San Francisco | 2 | 2008 | 64 | 0.070 |
Why?
|
| Infant | 1 | 2010 | 1171 | 0.070 |
Why?
|
| Employment | 1 | 2006 | 42 | 0.070 |
Why?
|
| Peptic Ulcer | 1 | 2006 | 14 | 0.070 |
Why?
|
| Glucose Intolerance | 1 | 2006 | 45 | 0.070 |
Why?
|
| Allergy and Immunology | 1 | 2005 | 4 | 0.070 |
Why?
|
| Hair | 1 | 2005 | 7 | 0.070 |
Why?
|
| Child, Preschool | 1 | 2010 | 1409 | 0.060 |
Why?
|
| Attitude to Health | 1 | 2007 | 164 | 0.060 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2006 | 43 | 0.060 |
Why?
|
| Pulmonary Medicine | 1 | 2005 | 19 | 0.060 |
Why?
|
| Mass Screening | 1 | 2011 | 661 | 0.060 |
Why?
|
| Nicotine | 1 | 2005 | 47 | 0.060 |
Why?
|
| Cardiomegaly | 1 | 2005 | 1 | 0.060 |
Why?
|
| Psychometrics | 3 | 2010 | 121 | 0.060 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2006 | 86 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 62 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2005 | 70 | 0.060 |
Why?
|
| Time | 1 | 2004 | 20 | 0.060 |
Why?
|
| Registries | 1 | 2006 | 471 | 0.060 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2005 | 63 | 0.060 |
Why?
|
| Radiography | 1 | 2004 | 39 | 0.060 |
Why?
|
| Internationality | 2 | 2016 | 14 | 0.060 |
Why?
|
| Docosahexaenoic Acids | 1 | 2004 | 7 | 0.060 |
Why?
|
| Principal Component Analysis | 2 | 2015 | 23 | 0.050 |
Why?
|
| Fasting | 1 | 2022 | 48 | 0.050 |
Why?
|
| Glucose | 1 | 2022 | 30 | 0.050 |
Why?
|
| Trastuzumab | 1 | 2022 | 14 | 0.050 |
Why?
|
| Anthracyclines | 1 | 2022 | 14 | 0.050 |
Why?
|
| Ventricular Function, Left | 1 | 2022 | 51 | 0.050 |
Why?
|
| Self Disclosure | 1 | 2001 | 22 | 0.050 |
Why?
|
| Stroke Volume | 1 | 2022 | 100 | 0.050 |
Why?
|
| Africa | 2 | 2011 | 6 | 0.050 |
Why?
|
| Liver | 1 | 2001 | 32 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 8 | 0.050 |
Why?
|
| Aorta | 1 | 2020 | 5 | 0.050 |
Why?
|
| Hospitals, Psychiatric | 1 | 2000 | 3 | 0.050 |
Why?
|
| Chromatin | 1 | 2020 | 5 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 23 | 0.050 |
Why?
|
| Acute-Phase Reaction | 1 | 2000 | 1 | 0.040 |
Why?
|
| Anticholesteremic Agents | 1 | 2000 | 14 | 0.040 |
Why?
|
| Kidney | 1 | 2020 | 52 | 0.040 |
Why?
|
| Glycated Hemoglobin A | 1 | 2001 | 216 | 0.040 |
Why?
|
| Weight Gain | 1 | 2001 | 173 | 0.040 |
Why?
|
| Arteriosclerosis | 1 | 2000 | 20 | 0.040 |
Why?
|
| Antioxidants | 1 | 2000 | 40 | 0.040 |
Why?
|
| Drug Synergism | 1 | 1999 | 3 | 0.040 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 1999 | 2 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 1999 | 6 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1999 | 129 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2000 | 145 | 0.040 |
Why?
|
| Suicide | 1 | 2000 | 123 | 0.040 |
Why?
|
| Linkage Disequilibrium | 2 | 2008 | 30 | 0.040 |
Why?
|
| Ultrasonography | 2 | 2009 | 35 | 0.040 |
Why?
|
| Clinical Coding | 1 | 2017 | 11 | 0.040 |
Why?
|
| Neural Networks (Computer) | 1 | 2017 | 1 | 0.040 |
Why?
|
| Emergency Medical Services | 2 | 2007 | 46 | 0.040 |
Why?
|
| Haplotypes | 2 | 2008 | 34 | 0.040 |
Why?
|
| Outcome Assessment (Health Care) | 2 | 2009 | 228 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2016 | 2 | 0.030 |
Why?
|
| Exercise | 1 | 2001 | 489 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2016 | 12 | 0.030 |
Why?
|
| Echocardiography | 2 | 2007 | 32 | 0.030 |
Why?
|
| Walk Test | 1 | 2015 | 5 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2015 | 9 | 0.030 |
Why?
|
| Automation | 1 | 2015 | 24 | 0.030 |
Why?
|
| Quality Control | 1 | 2015 | 45 | 0.030 |
Why?
|
| Pedigree | 1 | 2015 | 60 | 0.030 |
Why?
|
| Risk-Taking | 1 | 2015 | 109 | 0.030 |
Why?
|
| Human Activities | 1 | 2014 | 1 | 0.030 |
Why?
|
| Biological Transport | 1 | 2013 | 2 | 0.030 |
Why?
|
| Models, Economic | 1 | 2013 | 19 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2003 | 22 | 0.030 |
Why?
|
| Heart Conduction System | 1 | 2013 | 4 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2013 | 38 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2003 | 54 | 0.030 |
Why?
|
| Cell Line | 1 | 2012 | 9 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2012 | 9 | 0.030 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2012 | 1 | 0.030 |
Why?
|
| Co-Repressor Proteins | 1 | 2012 | 1 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2012 | 13 | 0.030 |
Why?
|
| Progesterone | 1 | 2012 | 5 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2012 | 22 | 0.030 |
Why?
|
| Testosterone | 1 | 2012 | 22 | 0.030 |
Why?
|
| Individuality | 1 | 2012 | 2 | 0.030 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2012 | 2 | 0.030 |
Why?
|
| Demography | 1 | 2012 | 101 | 0.030 |
Why?
|
| Twins, Monozygotic | 1 | 2012 | 12 | 0.030 |
Why?
|
| Patient Selection | 1 | 2003 | 190 | 0.020 |
Why?
|
| Menopause | 1 | 2012 | 68 | 0.020 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2012 | 99 | 0.020 |
Why?
|
| Far East | 1 | 2011 | 6 | 0.020 |
Why?
|
| Asia | 1 | 2011 | 15 | 0.020 |
Why?
|
| Europe | 1 | 2011 | 42 | 0.020 |
Why?
|
| Nitric Oxide Donors | 1 | 2011 | 3 | 0.020 |
Why?
|
| Mutation | 1 | 2012 | 128 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2011 | 5 | 0.020 |
Why?
|
| Observer Variation | 1 | 2010 | 37 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2010 | 3 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 218 | 0.020 |
Why?
|
| Multifactorial Inheritance | 1 | 2010 | 20 | 0.020 |
Why?
|
| Body Size | 1 | 2010 | 31 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2010 | 58 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2010 | 23 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2010 | 81 | 0.020 |
Why?
|
| Emigration and Immigration | 1 | 2009 | 15 | 0.020 |
Why?
|
| Helplessness, Learned | 1 | 2009 | 1 | 0.020 |
Why?
|
| Cystatin C | 1 | 2009 | 15 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2010 | 125 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2010 | 64 | 0.020 |
Why?
|
| Korea | 1 | 2009 | 9 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2009 | 10 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2009 | 89 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2010 | 177 | 0.020 |
Why?
|
| Creatinine | 1 | 2009 | 65 | 0.020 |
Why?
|
| Propensity Score | 1 | 2009 | 85 | 0.020 |
Why?
|
| Anxiety | 1 | 2009 | 150 | 0.020 |
Why?
|
| 5-Lipoxygenase-Activating Proteins | 1 | 2008 | 4 | 0.020 |
Why?
|
| Lung Volume Measurements | 1 | 2008 | 2 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2008 | 12 | 0.020 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2007 | 3 | 0.020 |
Why?
|
| Fibrinogen | 1 | 2007 | 13 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 8 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2007 | 37 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2007 | 5 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2007 | 15 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2007 | 16 | 0.020 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2007 | 23 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2007 | 5 | 0.020 |
Why?
|
| Confounding Factors (Epidemiology) | 1 | 2007 | 86 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2007 | 33 | 0.020 |
Why?
|
| Mice | 1 | 2007 | 68 | 0.020 |
Why?
|
| Psychology | 1 | 2006 | 16 | 0.020 |
Why?
|
| Absenteeism | 1 | 2006 | 24 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2006 | 50 | 0.020 |
Why?
|
| ROC Curve | 1 | 2006 | 77 | 0.020 |
Why?
|
| Leisure Activities | 1 | 2006 | 31 | 0.020 |
Why?
|
| Utilization Review | 1 | 2005 | 53 | 0.020 |
Why?
|
| Base Sequence | 1 | 2005 | 19 | 0.020 |
Why?
|
| Heart Atria | 1 | 2005 | 3 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2005 | 104 | 0.010 |
Why?
|
| Cotinine | 1 | 2001 | 7 | 0.010 |
Why?
|
| Chicago | 1 | 2001 | 26 | 0.010 |
Why?
|
| Alabama | 1 | 2001 | 23 | 0.010 |
Why?
|
| Minnesota | 1 | 2001 | 53 | 0.010 |
Why?
|
| Causality | 1 | 2001 | 40 | 0.010 |
Why?
|
| Urban Health | 1 | 2001 | 38 | 0.010 |
Why?
|
| Bilirubin | 1 | 2000 | 30 | 0.010 |
Why?
|
| Vitamins | 1 | 2000 | 64 | 0.010 |
Why?
|